Considerations for Start-Up Biotech Company Valuation
DOI:
https://doi.org/10.5912/jcb648Keywords:
valuation, bio-tech, start-up, risk, biologicsAbstract
The prospect of government regulation, product liability lawsuits, and customer reliance on third-party payers contribute to the complexity of valuing biotech start-ups. In addition, the inherent complexity of biologic drug manufacturing and storage creates secondary risks that must be considered in a valuation.
References
Adamski, Jakub, Harald Herholz, Silvio Garattini, Kristina Garuolienè, Brian Godman, Lars L
Gustafsson, Roland Gustafsson, Alan Haycox, Saira Jan, Marija Kalaba, Ott Laius, Gabriella Ofierska-Sujkowska, Bogusława Osińska, Catherine Sermet, Kamila Wendykowska, Corrine Zara. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. Accessed on-line at: http://www.biomedcentral.com/1472-6963/10/153.
Annual Report on Whistleblower Program, U.S. SEC, October 2010.
Blackstone, Erwin A. and Joseph P. Fuhr, Jr. The Future of Competition in the Biologics Market.
Temple J Science Technology & Environment L., Vol. XXXI, 2012. 3-4, 25.
Boat, Thomas F. and Marilyn J. Field, editors. Rare diseases and Orphan Products: Accelerating
Research and Development. The National Academies Press: Washington, D.C., 2010. 156, 181, 189-190, 195.
Brumley, James. Why Big Pharma Doesn't Really Need (Or Even Want) A Pipeline. January 17,
Accessed on-line at: http://seekingalpha.com/article/320013-why-big-pharma-doesnt-really-need-or-even-want-a-pipeline.
Cosner, Krista L. Are You Prepared to Defend Biopharmaceuticals? DRI, 2010. 48-78.
Accessed on-line at http://www.drinkerbiddle.com/Templates/media/files/publications/2011/are-you-prepared-to-defend-biopharmaceuticals.pdf.
Danzon, Patricia M. Economics of the Pharmaceutical Industry. NBER Reporter, Fall 2006. 15.
Danzon, Patricia M. and Eric L. Keuffel. Regulation of the Pharmaceutical-Biotechnology
Industry. Revised January 15, 2013. Located on-line from the National Bureau of Economic Research at: http://www.nber.org/chapters/c12572.pdf. Page 7-8, 14, 56.
DiMasi, J. A., J. M. Reichert, L. Feldman, and A. Malins. Clinical Approval Success Rates for
Investigational Cancer Drugs. Clinical Pharmacology & Therapeutics, 2013. 94, 3, 329–335.
Ernst & Young. Strategic Business Risk: Pharmaceuticals 2008. 7, 9-11.
Evaluating Pharmaceutical Companies. November 3, 2011. Accessed on-line at:
http://www.investopedia.com/articles/06/drugmarket.asp.
False Claim Recoveries Top $3 Billion in 2010, Compliance Week, November 29, 2010.
Franco, Pedro. Orphan Drugs: The Regulatory Environment. Drug Discovery Today, Vol. 18
(3/4). February 2013. 169.
Friedhoff, Lawrence T. New Drug: An Insider’s Guide to the FDA’s New Drug Approval
Process for Scientist, Investors and Patients. 2009. 111, 120, 127, 196.
General Information on Counterfeit Medicines. World Health Organization, 2013. Accessed on-
line at: http://www.who.int/medicines/services/counterfeit/overview/en/.
Garnier, Jean-Pierre. Rebuilding the R&D Engine in Big Pharma. Harvard Business Review;
May 2008. 72.
Girotra, Terwiesch, and Ulrich. Valuing R&D Project in a Portfolio. Management Science
(9), 1453.
Hall, Linda, Helen Lawton Smith, and Sharmistha Bagchi-Sen. The US Biotechnology Industry:
Industry Dynamic and Policy. Environment and Planning C: Government and Policy (22) 2004. 199. 206.
Interpretation of News: 12 Years of Exclusivity for Biologics Drugs. Nature Biotechnology’s
Bioentrepreneur Forum: Topic. April 4, 2010. Accessed on-line at: http://network.nature.com/groups/bioentrepreneur/forum/topics/7082.
Issues Monitor: Sharing Knowledge on Topical Issues in the Pharmaceuticals Industry. KPMG
International. April 2011 (9). 4.
Kubik, Thomas T. Beer Cooler Biologics: The Dangers of Counterfeit Drugs. The Police Chief,
vol. LXXV, no. 8, August 2008. Accessed on-line at http://www.policechiefmagazine.org/magazine/index.cfm?fuseaction=display_arch&artic
le_id= 1575&issue_id=82008.
Lazonick, William and Öner Tulum. US Biopharmaceutical Finance and the Sustainability of the
Biotech Business Model. Research Policy 40, 2011. 1170.
Massoudi, Arash and Andrew Ward. Bubble Fears Amid Surge in US Biotech Listings. Financial
Times. February 10, 2014. 13.
Perri, Matthew and Brent L. Rollins. Pharmaceutical Marketing. United States: Jones & Barlett
Learning, 2014. 90-92.
Recent Health Care and False Claims Act Developments. Kutak Rock LLP, April 16, 2010.
Accessed on-line at: http://www.kutakrock.com/files/Publication/523dc22e-03d4-418a-af89-c930826c4a26/Presentation/PublicationAttachment/b76849e8-2935-4520-b34f-e4bbae7f6207/PPACA_050510.pdf.
Rees, Hedly. Supply Chain Management in the Drug Industry. John Wiley & Sons Publishing;
New Jersey, 2011. 109-110, 215.
Roy, Avik S.A. Stifling New Cures: The True Cost of Lengthy Drug Trials. Project FDA Report,
No. 5 April 2012. Manhattan Institute for Policy Research. Accessed on-line at: http://www.manhattan-institute.org/html/fda_05.htm.
Satisfaction Guaranteed or Your Money Back. Biotech. Healthcare at 15 (Oct./Nov.2009) Cited
in: Blackstone, Erwin A. and Joseph P. Fuhr, Jr. The Future of Competition in the Biologics Market. Temple J Science Technology & Environment L., Vol. XXXI, 25.
Steinberg, Jeffrey. Managing the Risks from Outsourcing. Ernst & Young, Strategic Business
Risk. 2008.16.
Steven, Silver, Industry Surveys: Biotechnology. Standard & Poor’s, February 24, 2011. Cited in
Blackstone, Erwin A. and Joseph P. Fuhr, Jr. The Future of Competition in the Biologics Market, Temple J Science Technology & Environment L., Vol. XXXI, 5.
Tambuyzer, Erik. “Rare Diseases, Orphan Drugs and Their Regulation: Questions and
Misconceptions.†Nature Reviews, Drug Discovery. Vol. 9, 2010. 921-922, 924, 927.
Wellman-Labadie, Oliver and Youwen Zhou. The US Orphan Drug Act: Rare Disease Research
Stimulator or Commercial Opportunity? Health Policy (95) 2010. 226.
